

CURRICULUM VITAE

PERSONAL INFORMATION

Name **MUELLER, JUDITH E.**
Address EHESP Paris
20 avenue George Sand
93210 La Plaine St Denis
Phone +33-(0)6.75.71.08.21
Courrier électronique judith.mueller@ehesp.fr
Language German (native), English and French (fluent in written and spoken)

PROFESSIONAL EXPERIENCE

Since 2011
EHESP FRENCH SCHOOL OF PUBLIC HEALTH, Rennes and Paris, France
- Professor in epidemiology, Departement of Quantitative Methods in Public Health
- Research affiliation at INSTITUT PASTEUR, Emerging Disease Epidemiology Unit
- Vice Director of the French Network of Doctoral Programmes in Public Health

2002 - 2011
AGENCE DE MEDECINE PREVENTIVE (AMP), Paris, France
Medical epidemiologist, Head of the research program on Meningitis and Pneumonia

2000 – 2002
GSF NATIONAL RESEARCH CENTER, Oberschleissheim, Germany
Medical epidemiologist, post-doc scientist

1997 – 1998
CHU KLINIKUM RECHTS DER ISAR, Munich, Germany
Intern (Arzt im Praktikum) in obstetrics and gynecology

EDUCATION AND TRAINING

2012
Université de Pierre et Marie Curie (Paris 6), Paris, France
HABILITATION A DIRIGER DES RECHERCHES (HDR)

2004 - 2008
Université de Pierre et Marie Curie (Paris 6), Ecole Doctorale-393, Paris, France
Epidemiology / Public Health
DIPLOME DE DOCTEUR (PHD)

1999 - 2000
Harvard School of Public Health, Boston, USA
Public Health, Concentration: Quantitative Methods
MASTER OF PUBLIC HEALTH

1990 -1997, 2000
Technische Universität München, Munich, Germany
Human Medicine
STAATSEXAMEN (MD), DR. MED. (ACADEMIC MEDICAL TITLE)

EXPERT CONTRIBUTIONS

since 2019 :

SAGE Working Group on Meningococcal Vaccines and Vaccination, World Health Organization (WHO).

since 2017:

Commission technique des vaccinations (CTV) at the Haute Autorité de la santé (HAS) (French NITAG).

May 2012 and April 2018:

Appointment as member of the **IHR Roster of experts** - Acute neurological syndrome or meningococcal disease

2014:

WHO Guideline development group: Meningitis outbreak response in sub-Saharan Africa

2012-13:

Systematic revue - Comparative effectiveness of infant immunization schedules against diphtheria, tetanus and pertussis. **Contract work for WHO-IVR / SAGE Working Group on Pertussis Vaccines**

November 2011:

MERIT Expert advisory group, at the MERIT Strategic Review Meeting

2008:

MenAfriVac Investment Case writing team (GAVI), consultation to WHO

1. Jean K, Raad H, Gaythorpe KAM, Hamlet A, **Mueller JE**, Hogan D, Mengistu T, Whitaker HJ, Garske T, Hocine MN. Assessing the impact of preventive mass vaccination campaigns on yellow fever outbreaks in Africa: a population-level self-controlled case-series study. *PLoS Medicine*, accepted
2. Donzel Godinot L, Sicsic J, Lachatre M, Bouvet E, Abiteboul D, Rouveix E, Pellissier G, Raude J, **Mueller JE**. Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers. *Vaccine*, in press
3. Escolano S, **Mueller JE**, Tuber-Bitter P. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under 5 years of age, in France. *EuroSurveillance*. 2020 25(34):200827ec. doi: 10.2807/1560-7917.ES.2020.25.34.200827ec.
4. **Mueller JE**. Meningococcal strain evolution, dusty dry air and respiratory tract infections: An explosive relationship. *EBioMedicine*. 2019;42:34-35. doi: 10.1016/j.ebiom.2019.03.067.
5. **Mueller JE**. Long-term effectiveness of MenAfriVac. *Lancet Infect Dis*. 2019;19(3):228-229. doi: 10.1016/S1473-3099(18)30725-4.
6. Koutangni T, Crépey P, Woringer M, Porgo S, Bicaba BW, Tall H, **Mueller JE**. Compartmental models for seasonal hyperendemic bacterial meningitis in the African meningitis belt. *Epidemiol Infect*. 2018. doi: 10.1017/S0950268818002625.
7. Woringer M, Martiny N, Porgo S, Bicaba BW, Bar-Hen A, **Mueller JE**. Atmospheric dust, early cases and localized meningitis epidemics in the African meningitis belt: an analysis using high spatial resolution data. *Envir Health Perspect*, 2018;126:97002. doi: 10.1289/EHP2752..
8. Yaro S, Njanpop Lafourcade BM, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo JB, Gessner B, Meda N, Borrow R, Trotter C, **Mueller JE**. Antibody persistence at the population level 5 years after mass vaccination with meningococcal serogroup A conjugate vaccine (PsA-TT) in Burkina Faso: Need for a booster campaign? *Clin Infect Dis*. 2018 doi: 10.1093/cid/ciy488.
9. Norheim G, **Mueller JE**, Njanpop-Lafourcade BM, Delrieu I, Findlow H, Borrow R, Xie O, Nagaputra J, Ramasamy R, Dold C, Tamekloe TA, Rollier CS, Watt H, Kere AB, Næss LM, Pollard AJ. Natural immunity against capsular group X *N. meningitidis* following an outbreak in Togo, 2007. *Vaccine*. 2018 pii: S0264-410X(18)30066-5. doi: 10.1016/j.vaccine.2018.01.031.
10. **Mueller JE**, Woringer M, Porgo S, Madec Y, Tall H, Martiny N, Bicaba BW. The association between respiratory tract infection incidence and localised meningitis epidemics: an analysis of high-resolution surveillance data from Burkina Faso. *Scientific Reports*. 2017; 7:11570. doi:10.1038/s41598-017-11889-4
11. Seanehia J, Treibich C, Holmberg C, Müller-Nordhorn J, Casin V, Raude J, **Mueller JE**. Quantifying population preferences around vaccination against severe but rare diseases: A conjoint analysis among French university students, 2016. *Vaccine*. 2017 35(20):2676-2684. doi: 10.1016/j.vaccine.2017.03.086.
12. Pivette M, Auvigne V, Guérin P, **Mueller JE**. Suivi en quasi-temps réel de la vaccination contre la grippe chez les 65 ans et plus en France à partir des ventes de vaccins en pharmacie. *Rev Epidemiol Santé Publique*. 2017 Feb 9. <http://dx.doi.org/10.1016/j.respe.2016.12.025>
13. Blake A, Njanpop-Lafourcade BM, Telles JN, Rajoharison A, Makawa MS, Agbenoko K, Tamekloe S, **Mueller JE**, Tall H, Gessner BD, Paranhos-Baccalà G, Moïsi JC. Evaluation of chest radiography, *lytA* real-time PCR, and other routine tests for diagnosis of community-acquired pneumonia and estimation of possible attributable fraction of pneumococcus in northern Togo. *Epidemiol Infect*. 2017 Feb;145(3):583-594. doi: 10.1017/S0950268816002211.
14. Moïsi JC, Makawa MS, Tall H, Agbenoko K, Njanpop-Lafourcade BM, Tamekloe S, Amidou M, **Mueller JE**, Gessner BD. Burden of pneumococcal disease in Northern Togo before the introduction of pneumococcal conjugate vaccine. *PLoS One*. 2017 Jan 23;12(1):e0170412. doi: 10.1371/journal.pone.0170412.
15. Agier L, Martiny N, Thiongane O, **Mueller JE**, Paireau J, Watkins ER, Irving TJ, Koutangni T, Broutin H. Towards understanding the epidemiology of *Neisseria meningitidis* in the African meningitis belt: a multi-disciplinary overview. *Int J Infect Dis*. 2017 Jan;54:103-112. doi:

RELATED
PUBLICATIONS
(CONTINUED)

- 10.1016/j.ijid.2016.10.032.
16. Maïnassara HB, Oumarou GI, Issaka B, Sidiki A, Idi I, Pelat JM, Fontanet A, **Mueller JE**. Evaluation of response strategies against epidemics due to *Neisseria meningitidis* C in Niger. *Trop Med Int Health*. 2017 Feb;22(2):196-204. doi: 10.1111/tmi.12815.
 17. Maïnassara HB, Paireau J, Idi I, Jusot JF, Moulia Pelat JP, Ouwe Missi Oukem-Boyer O, Fontanet A, **Mueller JE**. Serogroup-specific characteristics of localized meningococcal meningitis epidemics in Niger 2002-2012 and 2015: analysis of health center level surveillance data. *PLoS One*. 2016 Sep 22;11(9):e0163110. doi:10.1371/journal.pone.0163110.
 18. Tall H, Yaro S, Kpoda HBN, Ouangraoua S, Trotter CL, Njanpop Lafourcade BM, Findlow H, Bai X, Martin C, Nwakamma I, Ouedraogo JB, Gessner BD, Borrow R, **Mueller JE**. Meningococcal seroepidemiology in Burkina Faso, one year after a mass immunization campaign with meningococcal serogroup A conjugate vaccine. *Clin Infect Dis* 2015; 61 Suppl 5:S540-6. **9**
 19. Maïnassara HB, Paireau J, Idi I, Pelat JM, Oukem-Boyer OO, Fontanet A, **Mueller JE**. Response strategies against meningitis epidemics after elimination of serogroup A meningococci, Niger. *Emerg Infect Dis*. 2015; 21:1322-9. **7**
 20. Blumental S, Moïsi J, Roalfe L, Zancolli M, Johnson M, Burbidge P, Borrow R, Yaro S, **Mueller JE**, Gessner BD, Goldblatt D. *S. pneumoniae* serotype 1 burden in the African meningitis belt: is there a lack of functionality in specific antibodies? *Clin Vaccine Immunol*. 2015; 22:404-12. **3**
 21. Koutangni T, Maïnassara HB, **Mueller JE**. Incidence, carriage and case-carrier ratios for meningococcal meningitis in the African meningitis belt: a systematic review and meta-analysis. *PLoS ONE* 2015; 10(2):e0116725. **3**
 22. Pivette M, **Mueller JE**, Crépey P, Bar-Hen A. Drug sales data analysis for outbreak detection of infectious diseases: a systematic literature review. *BMC Infect Dis*. 2014; 14:604. **3**
 23. Banke-Thomas AO, Wilton-Waddell OE, Kouraogo SF, **Mueller JE**. Current evidence supporting obstetric fistula prevention strategies in sub Saharan Africa: a systematic review of the literature. *Afr J Reprod Health*. 2014 Sep;18(3):118-27.
 24. Paireau J, Maïnassara HB, Jusot JF, Collard JM, Idi I, Moulia-Pelat JP, **Mueller JE**, Fontanet A. Spatio-temporal factors associated with meningococcal meningitis annual incidence at the health centre level in Niger, 2004–2010. *PLoS Negl Trop Dis* 2014; 8: e2899. **3**
 25. Pivette M, **Mueller JE**, Crépey P, Bar-Hen A. Surveillance of gastrointestinal disease in France using drug sales data. *Epidemics* 2014; 8:1-8. **3**
 26. Comboroure JC, **Mueller JE**. Perception de la vaccination et rôle du pharmacien d'officine: une enquête auprès des étudiants en dernière année de pharmacie en France. [Perception of vaccination and role of the pharmacist: a survey among final year pharmacy students in France.] *Ann Pharm Fr* 2014; 72:122-31. **1**
 27. Yaro S, Njanpop-Lafourcade BM, Drabo A, Idohou RI, Kroman SS, Sanou O, Traoré Y, Sangaré L, Diagbouga SP, Koeck JL, Borrow R, Gessner BD, **Mueller JE**. Anti-pneumococcal seroprevalence and pneumococcal carriage during a meningococcal epidemic in Burkina Faso, 2006. *J Infect Dis* 2014; 209:1241-50. **7**
 28. Banke-Thomas AO, Kouraogo SF, Siribie A, Taddese HB, **Mueller JE**. Knowledge of obstetric fistula prevention amongst young women in urban and rural Burkina Faso: a cross-sectional study. *PLoS ONE* 2013;8:e85921. **3**
 29. Xie O, Pollard AJ, **Mueller JE**, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. *Vaccine* 2013; 31: 2852-61. **4**
 30. Trotter CL, Yaro S, Njanpop-Lafourcade BM, Drabo A, Kroman SS, Idohou RS, Sanou O, Bowen L, Findlow H, Diagbouga S, Gessner BD, Borrow R, **Mueller JE**. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A *Neisseria meningitidis* by age in Burkina Faso 2008. *PLoS ONE* 2013; 8:e55486. **3**
 31. Dakar discussion group on priorities for research on epidemic meningococcal disease in Africa, Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, Caugant D, Clark T, Collard JM, Djingarey M, Goldblatt D, Greenwood B, Griffiths U, Hajjeh R, Hassan-King M, Hugonnet S, Kimball AM, LaForce M, MacLennan C, Maiden MC, Manigart O, Mayer L, Messonnier N, Moïsi J, Moore K, Moto DD, **Mueller J**, Nascimento M, Obaro S, Ouedraogo R, Page AL, Perea W, Pluschke G, Preziosi MP, Sow S, Stephens D, Stuart J, Thomson M, Tiendrebeogo S, Trape JF, Vernet G. Priorities for research on meningococcal disease and the impact of serogroup A

- vaccination in the African meningitis belt. *Vaccine* 2013; 31:1453-7. **4**
32. **Mueller JE.** Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. *Trop Med Internat Health.* 2013;18:58-64. **2**
 33. **Mueller JE,** Yaro S, Ouédraogo MS, Levina N, Njanpop-Lafourcade BM, Tall H, Idohou RS, Sanou O, Kroman SS, Drabo A, Nacro B, Millogo A, van der Linden M, Gessner BD. Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults. *PLoS ONE.* 2012; 7:e52464 **3**
 34. Won H, Yang S, Gaydos C, Hardick J, Ramachandran P, Hsieh YH, Kecojevic A, Njanpop-Lafourcade BM, **Mueller JE,** Tamekloe TA, Badziklou K, Gessner BD, Rothman RE. A broad range assay for rapid detection and etiologic characterization of bacterial meningitis: performance testing in samples from sub-Sahara. *Diagn Microbiol Infect Dis.* 2012;74:22–7. **3**
 35. Gessner BD, Sanou O, Drabo A, TamekloeTA, Yaro S, Tall H, Moisi JC, **Mueller JE,** Njanpop-Lafourcade BM. Pneumococcal serotype distribution along meningitis cases from Togo and Burkina Faso during 2007-2009. *Vaccine* 2012; 30 suppl 6: G41-5. **4**
 36. Tall H, Hugonnet S, Donnen P, Dramaix-Wilmet M, Kambou L, Drabo F, **Mueller JE.** Definition and characterization of localized meningitis epidemics in Burkina Faso. *BMC Infect Dis* 2012;12:2 (**C; 2,83**)
 37. **Mueller JE,** Yaro S, Njanpop-Lafourcade BM, Drabo A, Idohou RS, Kroman SS, Sanou O, Diagbouga S, Traoré Y, Sangaré L, Borrow R, Gessner BD. Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage and immunity. *J Infect Dis* 2011;204:1787-95. (**B; 6,288 en 2010**)
 38. Delrieu I, Yaro S, Tamekloé TAS, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A, Gessner BD, Kambou JL, **Mueller JE.** Emergence of epidemic *Neisseria meningitidis* serogroup X meningitis in Togo and Burkina Faso. *PLoS ONE* 2011;6:e19513. (**B; 4,411 en 2010**)
 39. Rose AMC, **Mueller JE,** Gerstl S? Njanpop-Lafourcade BM, Page AM, Nicolas P, Ouédraogo Traoré R, Caugant DA, Guérin PJ. Meningitis dipstick rapid test: evaluating diagnostic performance during an urban *Neisseria meningitidis* serogroup A outbreak, Burkina Faso, 2007. *PLoS ONE* 2010;5:e11086. **3**
 40. Cissé MF, Breugelmans JG, Bâ M; Diop MB, Faye PC, Mhlanga B, **Mueller JE,** Koffi D, Gessner BD. The elimination of *Haemophilus influenzae* type b meningitis following conjugate vaccine introduction in Senegal. *Pediatr Infect Dis J* 2010;29:499-503. **6**
 41. **Mueller JE,** Gessner BD. A hypothetical model for meningococcal meningitis in the African meningitis belt. *Int J Infect Dis* 2010;15:e553-9. **2**
 42. Gessner BD, **Mueller JE,** Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. *BMC Infect Dis.* 2010;10:22. (**C; 2,825**)
 43. Njanpop Lafourcade BM, Sanou O, van der Linden M, Levina N, Karanfil M, Yaro S, Tamekloe TA, **Mueller JE.** Serotyping pneumococcal meningitis cases in the African meningitis belt using multiplex PCR on cerebrospinal fluid. *J Clin Microbiol* 2010;48:612-4. (**B; 4,220**)
 44. **Mueller JE,** Bessaud M, Huang QS, Martinez LC, Barril PA, Morel V, Balanant J, Bocacao J, Hewitt J, Gessner BD, Delpeyroux F, Nates SV. Environmental poliovirus surveillance during OPV and IPV use in Córdoba Province, Argentina. *Appl Environ Microbiol* 2009;75:1395-401. (**B; 3,686**)
 45. Traore Y, Tameklo TA, Njanpop-Lafourcade BM, Lourd M, Yaro S, Njamba D, Drabo A, **Mueller JE,** Koeck JL, Gessner BD. Pneumococcal meningitis in Burkina Faso and Togo is common, seasonal, affects all age groups, and is highly lethal. *Clin Infect Dis* 2009;48:S181-9. (**A; 8,915**)
 46. Moïsi JC, Saha SK, Falade AG, Njanpop-Lafourcade BM, Oundo J, Zaidi AKM, Afroj S, Bakare RA, Buss JK, Lasi R, Odekanmi AA, Sangaré L, **Mueller J,** Scott JAG, Deloria Knoll M, Levine OS, Gessner BD. Enhanced diagnosis of pneumococcal meningitis using the Binax NOW® *S. pneumoniae* immuno-chromatographic test: a multi-site study. *Clin Infect Dis* 2009;48(suppl):49-56. (**A; 8,915**)
 47. **Mueller JE,** Yaro S, Madec Y, Somda PK, Idohou RS, Njanpop Lafourcade BM, Drabo A, Tarnagda Z, Sangaré L, Traoré Y, Fontanet A, Gessner BD. Association of respiratory tract infection symptoms and air humidity with meningococcal carriage in Burkina Faso. *Trop Med Int*

Health 2008;13:1543-52. (C; 2,312)

48. Muganga N, Uwimana J, Fidele N, Gahimbare L, Gessner BD, **Mueller JE**, Mhlanga BR, Katsande R, Herninger KH, Rugambwa C. *Haemophilus influenzae* type b conjugate vaccine impact against purulent meningitis in Rwanda. **Vaccine** 2007;25:7001-5. (B; 3,377)
49. **Mueller JE**, Sangaré L, Njanpop-Lafourcade BM, Tarnagda Z, Traoré Y, Yaro S, Borrow R, Gessner BD, Nicolas P. Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. **Emerging Infect Dis** 2007;13:847-54. (B; 5,775)
50. Yaro S, Traoré Y, Tarnagda Z, Sangaré L, Njanpop-Lafourcade BM, Drabo A, Findlow H, Borrow R, Nicolas P, Gessner BD, **Mueller JE**. Meningococcal carriage and immunity in western Burkina Faso, 2003. **Vaccine** 2007;25(suppl):A42-6. (B; 3,377)
51. Adjogble KL, Lourd M, Njanpop-Lafourcade BM, Traore Y, Hlomaschi AF, Amegatse KA, Agbenoko K, Sanou O, Sita K, **Mueller JE**, Gessner BD. The epidemiology of *Neisseria meningitidis* meningitis in Togo during 2003-2005. **Vaccine** 2007; 25(suppl):A47-52. (B; 3,377)
52. Findlow H, Vogel U, **Mueller JE**, Curry A, Njanpop-Lafourcade BM, Claus H, Gray S, Yaro S, Traoré Y, Sangaré L, Nicolas P, Gessner BD, Borrow R. Three cases of invasive meningococcal disease in Burkina Faso caused by a *capsule null locus* strain circulating among healthy carriers. **J Infect Dis** 2007;195:1071-7. (A; 6,035)
53. Traoré Y, Njanpop-Lafourcade BM, Adjogble KLS, Lourd M, Yaro S, Nacro B, Drabo A, Parent du Chatelet I, **Mueller JE**, Taha MK, Borrow R, Nicolas P, Alonso JM, Gessner BD. The rise and fall of epidemic *Neisseria meningitidis* serogroup W135 meningitis in Burkina Faso, 2002-5. **Clin Infect Dis** 2006;43:817-822. (A; 6,186)
54. Daza P, Banda R, Misoya K, Katsulukuta A, Gessner BD, Katsande R, Mhlanga BR, **Mueller JE**, Nelson CB, Phiri A, Molyneux EM, Molyneux ME. The impact of routine infant immunization with *Haemophilus influenzae* type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. **Vaccine** 2006;24:6232-9. (B; 3,159)
55. **Mueller JE**, Borrow R, Gessner BD. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. **Expert Rev Vaccines** 2006; 5(3). (D; 2.111 en 2007)
56. **Mueller JE**, Yaro S, Traoré Y, Sangaré L, Tarnagda Z, Njanpop-Lafourcade BM, Borrow R, Gessner BD. *Neisseria meningitidis* serogroup W135 and A: carriage and immunity in Burkina Faso, 2003. **J Infect Dis** 2006;193:812-20. (A; 5.363)
57. **Mueller JE**, Frye C, Brasche S, Heinrich J. Association of hormone replacement therapy with bronchial hyper-responsiveness. **Respiratory Med** 2003;97:990-2. (D; 1.419)
58. Frye C, **Mueller JE**, Niedermeier K, Wjst M, Heinrich J. Maternal oral contraceptive use and atopic diseases in the offspring. **Allergy** 2003;58:229-32. (B; 3.161)
59. **Mueller JE**, Döring A, Heier M, Löwel H. Prevalence and determinants of hormone replacement therapy in German women 1984-1995. **Maturitas** 2002;43:95-104. (revue non recensée; 2.068)
60. Seifert-Klauss V, **Mueller JE**, Luppä PB, Probst R, Wilker J, Höß C, Treumann T, Kastner C, Ulm K. Bone metabolism during the perimenopausal transition: a prospective study. **Maturitas** 2002;41:23-33. (revue non recensée; 2.068)
61. Barrett-Connor E, **Mueller JE**, von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. **J Clin Endocrinol Metab** 2000;85:219-223. (revue non classée pour 2000; 5.447)

Publications in national peer-reviewed journals

1. Raude J, **Mueller J**. Les attitudes des Français face à la vaccination : une évolution préoccupante. *Médecine*. Avril 2017, 171-4. DOI: 10.1684/med.2017.195.
2. Pivette M, Auvigne V, Guérin P, **Mueller JE**. Suivi en quasi-temps réel de la vaccination contre la grippe chez les 65 ans et plus en France à partir des ventes de vaccins en pharmacie. *Rev Epidemiol Santé Publique*. 2017 Feb 9. pii: S0398-7620(17)30001-9.

<http://dx.doi.org/10.1016/j.respe.2016.12.025>

3. **Mueller JE**, Kitar S, Bloch MA. Le Réseau doctoral en santé publique. *Cahiers de fonction publique* 2014; 348:70-3.
4. Comboroure JC, **Mueller JE**. Perception de la vaccination et rôle du pharmacien d'officine : une enquête auprès des étudiants en dernière année de pharmacie en France. [Perception of vaccination and role of the pharmacist: a survey among final year pharmacy students in France.] *Annales pharmaceutiques françaises* 2014;72:122-31.
5. Löwel H, Kuch B, Meisinger C, **Müller J**, Hörmann A. Der Koronarpatient im Alter aus epidemiologischer Sicht. [The elderly coronary patient from the epidemiological point of view.] *Herzmedizin*. 2001;18:2-12. (revue non recensée; pas de facteur d'impact)